MEDP logoMEDP
Medpace Holdings Inc

1,548
Loading...
Loading...
News
all
press releases
SOLV vs. MEDP: Which Stock Is the Better Value Option?
SOLV vs. MEDP: Which Stock Is the Better Value Option?
Zacks·5h ago
News Placeholder
More News
News Placeholder
Medpace (MEDP) Stock Declines While Market Improves: Some Information for Investors
Medpace (MEDP) closed at $536.17 in the latest trading session, marking a -1.42% move from the prior day.
Zacks·22h ago
News Placeholder
HTFL Gains FDA Clearance & Cigna Coverage for Next Gen Plaque Analysis
Heartflow secures FDA clearance and Cigna coverage for its Next Gen Plaque Analysis, boosting accuracy and nationwide access.
Zacks·4d ago
News Placeholder
Medpace (MEDP) Dips More Than Broader Market: What You Should Know
In the most recent trading session, Medpace (MEDP) closed at $487.95, indicating a -1.88% shift from the previous trading day.
Zacks·8d ago
News Placeholder
TMDX Partners With Mercedes-Benz to Launch Organ Transport Network
TransMedics collaborates with Mercedes-Benz to launch Italy's first organ transport network, expanding its OCS model beyond the United States.
Zacks·8d ago
News Placeholder
STXS Stock Gains as Erasmus Medical Adopts Its Genesis Robotic System
Stereotaxis stock gains as Erasmus Medical adopts Genesis robotic system, marking a milestone in cardiac arrhythmia care.
Zacks·10d ago
News Placeholder
Reasons to Hold Fresenius Medical Stock in Your Portfolio for Now
FMS acquisitions, partnerships and global reach fuel growth, though rising costs weigh on near-term prospects.
Zacks·10d ago
News Placeholder
Stryker Expands R&D Facility in India to Boost Medtech Innovation
SYK expands its Bangalore R&D hub to accelerate robotics, AI and digital health innovation while deepening ties with India's talent pool.
Zacks·11d ago
News Placeholder
Reasons to Hold AngioDynamics Stock in Your Portfolio for Now
ANGO benefits from NanoKnife, clinical milestones and a balanced portfolio despite tariff headwinds.
Zacks·11d ago
News Placeholder
Reasons to Retain Cooper Companies Stock in Your Portfolio for Now
COO's premium lens strategy, MiSight myopia leadership, and fertility portfolio fuel long-term growth despite near-term headwinds.
Zacks·11d ago

Latest MEDP News

View

Advertisement|Remove ads.

Advertisement|Remove ads.